Christine Knuehl

Title: Christine Knuehl: Innovator in Biopharmaceuticals

Introduction

Christine Knuehl is a prominent inventor based in Darmstadt, Germany. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative antibody therapies. With a total of four patents to her name, her work focuses on enhancing tumor selectivity and inhibition through advanced immunoglobulin molecules.

Latest Patents

One of her latest patents is titled "Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof." This patent describes a heterodimeric bispecific immunoglobulin molecule that includes a first Fab or scFv fragment specifically binding to EGFR and a second Fab or scFv fragment binding to c-MET. The patent details the structural components of the antibody, including an antibody hinge region, CH2 domain, and CH3 domain, which facilitate hybrid protein-protein interactions. Another notable patent is related to "Biological materials related to HER3," which encompasses amino acid sequences directed against HER3, along with the corresponding nucleic acids and methods for their preparation. These innovations have potential applications in prophylactic, therapeutic, and diagnostic purposes.

Career Highlights

Christine has worked with notable companies in the biopharmaceutical sector, including Ablynx N.V. and Merck Patent GmbH. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in antibody therapies.

Collaborations

Christine has collaborated with esteemed colleagues such as Bjoern Hock and Robert Hofmeister. These partnerships have further enriched her work and expanded the impact of her innovations in the field.

Conclusion

Christine Knuehl is a trailblazer in the biopharmaceutical industry, with her patents paving the way for advancements in cancer treatment. Her dedication to innovation continues to inspire future developments in the field.